Kodiak Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Kodiak Sciences's estimated annual revenue is currently $15.7M per year.
- Kodiak Sciences's estimated revenue per employee is $141,036
- Kodiak Sciences's total funding is $1B.
Employee Data
- Kodiak Sciences has 111 Employees.
- Kodiak Sciences grew their employee count by 0% last year.
Kodiak Sciences's People
Name | Title | Email/Phone |
---|---|---|
1 | SVP, Chemical Development & Manufacturing | Reveal Email/Phone |
2 | SVP, Discovery Medicine | Reveal Email/Phone |
3 | VP Biometrics and Clinical Data Science | Reveal Email/Phone |
4 | SVP, Quality Operations | Reveal Email/Phone |
5 | SVP, Digital Transformation and CIO | Reveal Email/Phone |
6 | VP, Corporate Controller | Reveal Email/Phone |
7 | VP, Finance | Reveal Email/Phone |
8 | VP, Chemistry | Reveal Email/Phone |
9 | VP, Senior Scientific Fellow | Reveal Email/Phone |
10 | VP, Biologics Development and Manufacturing | Reveal Email/Phone |
Kodiak Sciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Kodiak Sciences?
Kodiak is a high-science retinal medicines development company. We are aspiring to build a dominant global retina franchise. We are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. Our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. In our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments. WORKING AT KODIAK We are passionate about preventing blindness and improving health. We take pride in scientific and operational excellence. The curiosity, creativity, and courage of our team members drives our progress. We highly value this culture and support it every way we can. Kodiak supports a vibrant and active lifestyle. We have a top benefits package. We are within walking distance to California Avenue shops, restaurants and public transportation.
keywords:N/A$1B
Total Funding
111
Number of Employees
$15.7M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kodiak Sciences News
Get Kodiak Sciences alerts: In other news, Director Bros. Advisors Lp Baker bought 133,414 shares of the stock in a transaction on Friday...
Kodiak Sciences Inc. (NASDAQ:KOD) Receives $45.89 Average Price Target from Brokerages. Posted by admin on Apr 13th, 2022.
Within the last quarter, Kodiak Sciences KOD has observed the following analyst ratings: Bullish, Somewhat Bullish, Indifferent...
PALO ALTO, Calif., Sept. 1, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high-prevalence retinal diseases, today announced new seven-year performance stock option ...
Kodiak Sciences Inc., a Palo Alto, CA-based development-stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, completed a $33m mezzanine private financing of convertible notes. Backers included Perceptive Advisors and ArrowMark Partners ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $18.1M | 113 | 38% | N/A |
#2 | $16.5M | 114 | -61% | N/A |
#3 | $16.5M | 114 | 10% | N/A |
#4 | $18.8M | 114 | 6% | N/A |
#5 | $15M | 114 | 25% | $18.5M |